1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Soligenix sets up consortium to develop thermostable vaccines

 
• By Sukaina Virji

Soligenix of the US, formerly known as DOR BioPharma, has established a consortium to develop thermostable technology to advance its RiVax vaccine and other rapidly acting vaccines. The consortium will be funded by a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the US National Institutes of Health (NIH).

Soligenix of the US, formerly known as DOR BioPharma, has established a consortium to develop thermostable technology to advance its RiVax vaccine and other rapidly acting vaccines. The consortium will be funded by a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the US National Institutes of Health (NIH).

The consortium will consist of partnerships between industry and academic researchers from different disciplines. Academic institutions participating include the University...

More from Immunological

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

Tonix Ready To Revive Fibromyalgia Market With Tonmya

 
• By Joseph Haas

The first new drug for fibromyalgia since 2009, Tonmya is a reformulation of cyclobenzaprine intended for chronic therapy. Tonix said the drug targets non-restorative sleep.

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

 
• By Alexandra Shimmings

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

 
• By Kevin Grogan

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

More from Therapeutic Category

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.